D. Boral Capital Reiterates Buy Rating for Omeros (NASDAQ:OMER)

Key Points

• D. Boral Capital has reaffirmed a "buy" rating for Omeros (NASDAQ:OMER) with a price target of $36.00.
• The current consensus rating for Omeros among analysts is "Moderate Buy," with a target price of $18.00.
• Omeros has a market cap of $224.40 million and traded at $3.83, significantly lower than its 12-month high of $13.60.

D. Boral Capital reissued their buy rating on shares of Omeros (NASDAQ:OMER - Free Report) in a report issued on Friday morning,Benzinga reports. D. Boral Capital currently has a $36.00 price objective on the biopharmaceutical company's stock.

OMER has been the topic of several other reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a report on Friday, May 16th. Wall Street Zen cut Omeros from a "hold" rating to a "sell" rating in a report on Friday, June 27th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $9.00 target price on shares of Omeros in a report on Friday, June 27th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $18.00.

Omeros Stock Down 4.3%

NASDAQ:OMER traded down $0.18 on Friday, reaching $3.97. 1,714,326 shares of the company's stock traded hands, compared to its average volume of 1,296,954. The stock has a 50-day simple moving average of $3.38 and a 200-day simple moving average of $6.24. The firm has a market cap of $245.19 million, a PE ratio of -1.50 and a beta of 2.16. Omeros has a 12 month low of $2.95 and a 12 month high of $13.60.

Omeros (NASDAQ:OMER - Get Free Report) last posted its quarterly earnings results on Thursday, May 15th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.05). On average, equities analysts anticipate that Omeros will post -3.09 earnings per share for the current year.

Institutional Investors Weigh In On Omeros

Several large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. increased its stake in Omeros by 3.0% during the first quarter. Vanguard Group Inc. now owns 3,237,256 shares of the biopharmaceutical company's stock worth $26,610,000 after acquiring an additional 95,599 shares during the last quarter. Nomura Holdings Inc. grew its stake in shares of Omeros by 136.2% during the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company's stock valued at $7,383,000 after buying an additional 430,932 shares during the last quarter. Two Sigma Investments LP grew its stake in shares of Omeros by 8.8% during the fourth quarter. Two Sigma Investments LP now owns 162,991 shares of the biopharmaceutical company's stock valued at $1,610,000 after buying an additional 13,201 shares during the last quarter. Bank of New York Mellon Corp grew its stake in shares of Omeros by 2.2% during the first quarter. Bank of New York Mellon Corp now owns 151,062 shares of the biopharmaceutical company's stock valued at $1,242,000 after buying an additional 3,321 shares during the last quarter. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of Omeros during the fourth quarter valued at approximately $1,488,000. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.